Endra Life Sciences GAAP EPS of -$0.05
- Endra Life Sciences press release (NASDAQ:NDRA): Q3 GAAP EPS of -$0.05.
- Operating expenses increased to $3.4 million in the third quarter of 2022 from $2.7 million in the same period in 2021. The increase was primarily due to higher spending related to commercializing the TAEUS system and ongoing product development.
- Cash and cash equivalents were $8.0 million as of September 30, 2022.